เอกสารอ้างอิง
[1]. Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, Gandhi MC, Kaplan SA, Kohler TS, Martin L, Parsons JK, Roehrborn CG, Stoffel JT, Welliver C, Wilt TJ. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management. J Urol. 2021 Oct;206(4):806-817.
[2]. McVary KT, O'Leary MP, Givens J. Medical treatment of benign prostatic hyperplasia. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on August 5, 2022).
[3]. Lexicomp, Inc. Alfuzosin: Drug information. In:Post TW, ed.UpToDate.Waltham: UpToDate; 2017 (Accessed on August 6, 2022).
[4]. Lexicomp, Inc. Doxazosin: Drug information. In:Post TW, ed.UpToDate.Waltham: UpToDate; 2017 (Accessed on August 6, 2022).
[5]. Lexicomp, Inc. Terazosin: Drug information. In:Post TW, ed.UpToDate.Waltham: UpToDate; 2017 (Accessed on August 6, 2022).
[6]. Lexicomp, Inc. Silodosin: Drug information. In:Post TW, ed.UpToDate.Waltham: UpToDate; 2017 (Accessed on August 6, 2022).
[7]. Lexicomp, Inc. Tamsulosin: Drug information. In:Post TW, ed.UpToDate.Waltham: UpToDate; 2017 (Accessed on August 6, 2022).
[8]. Manjunatha R, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Hanumantharaju BK. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia. Indian J Pharmacol. 2016 Mar-Apr;48(2):134-40.
[9]. Fusco F, Palmieri A, Ficarra V, Giannarini G, Novara G, Longo N, Verze P, Creta M, Mirone V. α1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies. Eur Urol. 2016 Jun;69(6):1091-101.